Siemens has launched new assays - Total PSA (TPSA) and free PSA (FPSA) - for use on the Dimension Vista1500 Intelligent Lab System in the US to detect prostate cancer.

The Intelligent Lab System udes patented Loci Advanced Chemiluminescence Technology which offers high sensitivity, quick reaction times, low sample volumes and simple homogeneous processing with no washing or separation steps, claims the company.

Loci technology uses an oxygen channeling mechanism that provides signal generation, and requires fewer reaction steps for all assays.

Siemens Healthcare Diagnostics IT Business Unit CEO Dave Hickey said it offers a full menu of PSA tests so that cancer centers, hospital and reference laboratories are able to provide clinicians with more choices to aid them in the detection, monitoring and management of their patients with prostate cancer.